OpenNashEarnings

Elevance Health (ELV) · Health Insurance

Elevance Health Q2 2026 earnings: summary, key numbers & outlook

Results filed 15 Jul 2026 · Quarter ended 30 Jun 2026

Slides (15 pages)Official transcript (PDF) ↗Press release ↗Investor relations ↗

Summaries and transcripts are machine-generated and can contain errors.

In brief

Elevance Health is accelerating targeted investments in cost management, member experience, provider connectivity and Carelon's value-based care while Medicaid cost pressure persists, aiming to return to at least 12% adjusted EPS growth in 2027.

Elevance repositioned its portfolio this quarter: Medicare Advantage and Employer Group risk membership shrank on purpose, and Medicaid membership fell as expected, while Individual ACA and Medicare Advantage performed better than planned. Total medical membership was about 44.9 million, down 469 thousand from the prior quarter, partly from a known commercial fee-based customer transition. Carelon kept scaling risk-based services and specialty pharmacy, though CarelonRx script volumes fell with health plan attrition.

Management plans to use a non-recurring below-the-line benefit to fund one-time investments in medical cost management, member experience, provider connectivity, operating efficiency and Carelon's value-based capabilities. It targets at least 12% adjusted EPS growth in 2027 off a $26.00 baseline. The tension is that Medicaid cost trend remains elevated, with 2026 described as a trough for Medicaid margins, and the plan depends on new investments paying off.

No call transcript for this quarter, so this summary also draws on: The Motley Fool ↗.

Slides & documents

Open the slide deck (PDF, 15 pages) ↗

Elevance Health Q2 2026 slide deck, page 1Elevance Health Q2 2026 slide deck, page 2Elevance Health Q2 2026 slide deck, page 3Elevance Health Q2 2026 slide deck, page 4Elevance Health Q2 2026 slide deck, page 5Elevance Health Q2 2026 slide deck, page 6

Showing the first 6 of 15 pages.

From Elevance Health investor relations

SEC filing

Key numbers

Operating revenue
$49.8 billion

up 0.8% from 2Q 2025

Shareholders' net income · GAAP
$1.5B

down 16.1% from a year ago

Diluted EPS · GAAP
$6.71

down 13.1% from a year ago

Adjusted diluted EPS · non-GAAP
$7.45

down 15.7% from a year ago

Operating gain · GAAP
$1.8B

down 27.3% from a year ago

Operating margin · GAAP
3.5%

down 140 bp from a year ago

Operating cash flow · GAAP
$1.9 billion

Benefit expense ratio
89.7%

up 80 basis points year over year

Segment or metricValueChange
Health Benefits operating revenue$42.7Bup 2.7%
CarelonRx operating revenue$11.2Bup 5.7%
Carelon Services operating revenue$8.0Bup 7.2%
Total medical membership44.9Mdown 1.5% from a year ago
Medicare Advantage membership1.9Mdown 15.9% from a year ago
Individual ACA operating revenue$2.7Bup 16.8%
CarelonRx quarterly adjusted scripts80.9Mdown 2.9% from a year ago
Carelon Services consumers served92.4Mdown 5.0% from a year ago
Where each number comes from
  • Operating revenue: “2Q 2026 operating revenue of $49.8 billion, up 0.8% from 2Q 2025”
  • Shareholders' net income: “Shareholders' net income | $1,463 | $1,743 | (16.1)% | $3,227 | $3,926 | (17.8)%”
  • Diluted EPS: “2Q 2026 diluted EPS1 of $6.71 and adjusted diluted EPS2 of $7.45”
  • Adjusted diluted EPS: “2Q 2026 diluted EPS1 of $6.71 and adjusted diluted EPS2 of $7.45”
  • Operating gain: “Total Operating Gain1,4 | $1,763 | $2,425 | (27.3)% | $3,849 | $5,595 | (31.2)%”
  • Operating margin: “Operating Margin1 | 3.5% | 4.9% Adjusted Operating Margin1,3 | 3.6% | 5.0%”
  • Operating cash flow: “Operating cash flow of $1.9 billion in the quarter reflects timing of a state Medicaid pass-through payment and underlying business strength.”
  • Benefit expense ratio: “The benefit expense ratio of 89.7 percent increased 80 basis points year over year, driven by expected elevated medical cost trend in our Government businesses”
  • Health Benefits operating revenue: “Health Benefits | $42,720 | $41,582 | 2.7% | $85,210 | $83,013 | 2.6%”
  • CarelonRx operating revenue: “CarelonRx | 11,250 | 10,643 | 5.7% | 21,850 | 20,759 | 5.3%”
  • Carelon Services operating revenue: “Carelon Services | 7,975 | 7,441 | 7.2% | 15,340 | 13,977 | 9.8%”
  • Total medical membership: “Total Medical Membership | 44,949 | 45,621 | 45,418 | (1.5)% | (1.0)%”
  • Medicare Advantage membership: “Medicare Advantage | 1,897 | 2,255 | 1,899 | (15.9)% | (0.1)%”
  • Individual ACA operating revenue: “Individual5 | 2,720 | 2,328 | 16.8% | 5,260 | 4,689 | 12.2%”
  • CarelonRx quarterly adjusted scripts: “CarelonRx Quarterly Adjusted Scripts | 80.9 | 83.3 | 80.3 | (2.9)% | 0.7%”
  • Carelon Services consumers served: “Carelon Services Consumers Served | 92.4 | 97.3 | 92.9 | (5.0)% | (0.5)%”

Copied from the press release ↗ and other documents in the SEC filing ↗. A figure is published only if its sentence is in those documents.

From the filingQ2 2026vs year agovs last quarter
Revenue$50.5B+1.4%+0.6%
Operating income$1.8B−27.3%−15.5%
Net income$1.5B−16.1%−17.1%
Diluted EPS$6.71−13.1%−16.1%
Free cash flow$1.6B−9.0%−60.3%
Operating margin3.5%−1.4 pts−0.7 pts

Calculated by code from XBRL, not by the model.

Outlook

MetricPeriodOutlook
Adjusted diluted EPSfull year 2026at least $27.00
Diluted EPS (GAAP)full year 2026at least $20.10
Operating cash flowfull year 2026at least $6.0 billion
Adjusted diluted EPS growth2027at least 12%

Key takeaways

  1. Portfolio repositioning is shrinking Medicare Advantage and group risk

    Medicare Advantage membership fell 15.9% year over year to 1,897 thousand, and Employer Group risk-based membership fell 5.5%. Management calls these intentional actions, trading volume for margin.

  2. Investments target cost detection, members, providers and Carelon

    Elevance is funding one-time work to detect cost trends earlier, guide members with personalized support, reduce provider friction such as avoidable denials, and expand Carelon. These are meant to make performance more consistent.

  3. Medicaid is the main pressure point

    Elevated Medicaid cost trend drove the higher benefit expense ratio, and Medicaid membership fell to 8,358 thousand. Management says Medicaid supports its unchanged margin guidance and views 2026 as a trough for Medicaid margins.

  4. Carelon is scaling risk-based services and CareBridge

    Carelon Services revenue grew on risk-based solutions, and plans include expanding CareBridge to new markets and growing external client relationships. Margins are held back by ongoing investment in the platform.

  5. Individual ACA and Medicare Advantage beat expectations

    Better-than-expected Medicare Advantage and Individual ACA performance led the benefit expense ratio. Individual ACA membership fell 7.5% sequentially to 1,317 thousand, but Individual revenue still grew 16.8% on pricing.

Charts

Revenue$50.5B+1.4% y/yQ2 2026
Q4 2024: $45.4B (worked out from the annual figure)Q4 ’24$45.4BQ1 2025: $48.9BQ1 ’25$48.9BQ2 2025: $49.8BQ2 ’25$49.8BQ3 2025: $50.7BQ3 ’25$50.7BQ4 2025: $49.7B (worked out from the annual figure)Q4 ’25$49.7BQ1 2026: $50.2BQ1 ’26$50.2BQ2 2026: $50.5BQ2 ’26$50.5BQ3 2026: $51.4BQ3 ’26$51.4B

Fourth quarter worked out from the annual figure.

Data
Q4 2024$45.4B *
Q1 2025$48.9B
Q2 2025$49.8B
Q3 2025$50.7B
Q4 2025$49.7B *
Q1 2026$50.2B
Q2 2026$50.5B
Q3 2026$51.4B
Diluted EPS (GAAP)$6.71−13.1% y/yQ2 2026
Q1 2025: $9.61Q1 ’25$9.61Q2 2025: $7.72Q2 ’25$7.72Q3 2025: $5.32Q3 ’25$5.32Q1 2026: $8.00Q1 ’26$8.00Q2 2026: $6.71Q2 ’26$6.71Q3 2026: $6.27Q3 ’26$6.27
Data
Q1 2025$9.61
Q2 2025$7.72
Q3 2025$5.32
Q1 2026$8.00
Q2 2026$6.71
Q3 2026$6.27

Fourth-quarter EPS appears once the press release is read; filings report it only for the full year.

Operating margin3.5%−1.4 pts y/yQ2 2026
Q4 2024: 1.5%Q4 ’241.5%Q1 2025: 6.5%Q1 ’256.5%Q2 2025: 4.9%Q2 ’254.9%Q3 2025: 2.6%Q3 ’252.6%Q4 2025: 0.6%Q4 ’250.6%Q1 2026: 4.2%Q1 ’264.2%Q2 2026: 3.5%Q2 ’263.5%Q3 2026: 2.5%Q3 ’262.5%
Data
Q4 20241.5%
Q1 20256.5%
Q2 20254.9%
Q3 20252.6%
Q4 20250.6%
Q1 20264.2%
Q2 20263.5%
Q3 20262.5%
Free cash flow$1.6B−9.0% y/yQ2 2026
Q4 2024: $384.0MQ4 ’24$384.0MQ1 2025: $821.0MQ1 ’25$821.0MQ2 2025: $1.8BQ2 ’25$1.8BQ3 2025: $775.0MQ3 ’25$775.0MQ4 2025: -$209.0MQ4 ’25-$209.0MQ1 2026: $4.1BQ1 ’26$4.1BQ2 2026: $1.6BQ2 ’26$1.6BQ3 2026: $1.0BQ3 ’26$1.0B
Data
Q4 2024$384.0M
Q1 2025$821.0M
Q2 2025$1.8B
Q3 2025$775.0M
Q4 2025-$209.0M
Q1 2026$4.1B
Q2 2026$1.6B
Q3 2026$1.0B

Operating cash flow minus capital expenditure, from cash flow statements.

Questions

What is Elevance investing in with its raised guidance?

A non-recurring below-the-line benefit funds one-time investments in medical cost management, member experience, provider connectivity, operating efficiency and Carelon's value-based capabilities. The aim is earlier detection of cost trends and less friction for members and providers.

How is Elevance's membership changing?

Medical membership was about 44.9 million, down 469 thousand from March. The causes were a known commercial fee-based customer transition and expected attrition in Individual ACA and Medicaid, plus deliberate repositioning in Medicare Advantage and Employer Group risk.

What is happening in Medicaid?

Medicaid cost trend remains elevated and Medicaid membership declined 4.3% year over year. Management says it is managing within its full-year margin framework, with rate alignment and targeted cost-of-care actions, and views 2026 as a trough for Medicaid margins.

How is Carelon performing?

Carelon operating revenue grew 6% as risk-based Carelon Services scaled and CarelonRx revenue per script rose. CarelonRx adjusted scripts fell 2.9% on health plan attrition, and specialty pharmacy profitability improved.

What is management's outlook beyond 2026?

Management expects to return to at least 12% adjusted EPS growth in 2027 off a 2026 baseline of $26.00. The long-term plan targets high single digit revenue growth and adjusted operating margin expanding to 5.0%-6.0%.